Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)

10.1164/rccm.200703-456SO

10.1016/S0140-6736(07)61380-4

10.1378/chest.117.2_suppl.1S

Minino AM, 2007, Natl Vital Stat Rep, 55, 1

10.1016/j.ejps.2010.01.004

10.1177/0091270009336353

10.5414/CPP47460

Jones PW, 2011, Respir Res [Internet]

10.1183/09031936.00099306

10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A1615

Fuhr R, 2011, Chest [Internet]

Singh D, Magnussen H, Kirsten A-M, Aclidinium bromide: a phase IIb, dose-finding study. In: British Thoracic Society Winter Meeting Programme and Abstracts Issue; 2011 December 7–9; London, UK. London, UK: Thorax; c2011. p. A172.

10.1183/09031936.05.00034805

10.1016/0885-3924(91)90520-E

10.1081/COPD-200050513

10.1081/COPD-200050666

10.1081/COPD-200053377

10.1136/thorax.58.5.399

10.1183/09031936.02.00269802

10.1183/09031936.02.00238702

Make BJ, 2003, Respir Care, 48, 1225

10.1056/NEJMoa0805800

10.1378/chest.124.4.1350

10.1016/j.rmed.2010.06.004

Bateman E, 2010, Int J Chron Obstruct Pulmon Dis, 5, 197

Mocarski M, Caracta C, Tourkodimitris S, Park G, Garcia Gil E, Setyawan J. Nighttime symptoms of COPD in a clinical trial population: prevalence and impact. In: American Thoracic Society International Conference Abstract Issue; 2011 May 13–18; Denver, CO. New York: Am J Respir Crit Care Med 2011; p. A1495.

10.1185/03007990903103006

10.1183/09031936.00051110

10.1080/15412550902724073

10.2165/00003495-200969050-00004

10.1080/15412550903140881

10.1016/j.rmed.2005.08.016

10.1177/1753465809344870

10.1016/j.clinthera.2005.05.009